-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

Benzinga·08/12/2026 16:24:11
Listen to the news
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.